Sign in
Active, not recruitingNo phase

DurAVR™ THV System: EMBARK Study

Key facts

Who runs it
Anteris Technologies Ltd.
Where
Georgia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
150 people, planned
Started
15 Nov 2021
Expected to end
Apr 2028
Type of study
Interventional
Treatments tested
  • DurAVR™ THV System
Record updated
26 June 2026

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 35 criteriaShow less

Who can take part

  • Symptomatic, severe aortic stenosis
  • Eligible for delivery of the DurAVR™ THV
  • Anatomy appropriate to accommodate safe placement of DurAVR™ THV
  • Understands the study requirements and the treatment procedures and provides written informed consent
  • Subject agrees to complete all required scheduled follow-up visits

Who cannot take part

  • Evidence of an acute myocardial infarction ≤ 30 days before the intended treatment
  • Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the index procedure
  • Need for emergency surgery for any reason
  • Currently participating in an investigational drug or another investigational device trial
  • Pre-existing prosthetic heart valve in any position
  • Determined inoperable/ineligible for surgery by the Heart Team
  • Untreated clinically significant Coronary Artery Disease (CAD) requiring revascularization
  • Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support
  • Symptomatic carotid or vertebral artery disease
  • GI bleeding within the past 3 months
  • A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated: aspirin, heparin, nitinol (titanium or nickel), ticlopidine and clopidogrel, contrast media
  • Life expectancy < 12 months due to associated non-cardiac co-morbid conditions
  • Other medical, social, or psychological conditions that in the opinion of an Investigator precludes the subject from appropriate consent
  • Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits)
  • Blood dyscrasias as defined: leukopenia (WBC < 1000mm3), thrombocytopenia (platelet count < 50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states
  • Ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤ 30% as measured by resting echocardiogram
  • End stage renal disease requiring chronic dialysis or creatinine clearance < 20 cc/min
  • Anatomical
  • Anatomy precluding safe placement of DurAVR™ THV
  • Unicuspid or bicuspid aortic valve
  • Severe aortic regurgitation
  • Severe mitral or severe tricuspid regurgitation requiring intervention
  • Moderate to severe mitral stenosis
  • Hypertrophic obstructive cardiomyopathy
  • Echocardiographic evidence of intracardiac mass, thrombus or vegetation requiring treatment
  • Severe basal septal hypertrophy with outflow gradient Clinical
  • Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack (TIA)
  • Ongoing sepsis, including active endocarditis
  • Subject refuses a blood transfusion
  • Subject belongs to a vulnerable population

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A prospective, non-randomized, single-arm, single-center, first-in-human study designed to evaluate the safety and feasibility of the DurAVR™ THV System in the treatment of subjects with symptomatic severe aortic stenosis.

The group in the trial

  • TreatmentTreatment being tested

    DurAVR™ THV System

    Treatment: DurAVR™ THV System

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: First In Human Study (EMBARK Study)
Record updated
26 June 2026